Lipocine (LPCN) Total Liabilities (2011 - 2025)
Lipocine's (LPCN) quarterly Total Liabilities came in at $2.5 million in Q4 2025, up 67.11% YoY from $1.5 million in Q4 2024, and up 30.92% on a QoQ basis from $1.9 million in Q3 2025.
Lipocine (LPCN) Total Liabilities (2011 - 2025) Analysis & Trends
Lipocine (LPCN) has 15 years of Total Liabilities data on file, last reported at $2.5 million in Q4 2025.
- Quarterly Total Liabilities rose 67.11% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (up 67.11% YoY) and the FY2025 annual result came in at $2.5 million, up 67.11% from the prior year.
- Total Liabilities improved to $2.5 million in Q4 2025, from $1.9 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $11.4 million in Q2 2021 to a low of $1.3 million in Q1 2025.
- A 5-year average of $3.4 million and a median of $2.0 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities slumped 79.85% — and 2025, when it surged 67.11%.
- Tracing LPCN's Total Liabilities over 5 years: stood at $6.9 million in 2021, then plunged by 72.4% to $1.9 million in 2022, then surged by 37.93% to $2.6 million in 2023, then plunged by 42.51% to $1.5 million in 2024, then surged by 67.11% to $2.5 million in 2025.
- The last three Total Liabilities figures came in at $2.5 million (Q4 2025), $1.9 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 86.33 Bn | 78.34 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 65.13 Bn | 59.95 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 60.47 Bn | 55.33 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.04 Bn | 27.73 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.48 Bn | 10.09 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.23 Bn | 26.39 Bn | - | 10.03 Bn |
| 10 | Lipocine | 11.42 Mn | -12.49 Mn | - | 2.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.53 Mn |
| Sep 30, 2025 | 1.93 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Mar 31, 2025 | 1.30 Mn |
| Dec 31, 2024 | 1.51 Mn |
| Sep 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | 1.82 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Dec 31, 2023 | 2.63 Mn |
| Sep 30, 2023 | 2.27 Mn |
| Jun 30, 2023 | 1.93 Mn |
| Mar 31, 2023 | 2.06 Mn |
| Dec 31, 2022 | 1.91 Mn |
| Sep 30, 2022 | 1.78 Mn |
| Jun 30, 2022 | 2.30 Mn |
| Mar 31, 2022 | 5.19 Mn |
| Dec 31, 2021 | 6.91 Mn |
| Sep 30, 2021 | 7.58 Mn |
| Jun 30, 2021 | 11.43 Mn |
| Mar 31, 2021 | 8.19 Mn |